Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg
Reference Brands: Vraylar®(US); Reagila®(EU)
Category: Antipsychotropic Drugs
Cariprazine is an atypical antipsychotic that works as a partial agonist at dopamine D2 and D3 receptors, with a higher affinity for D3, and serotonin 5-HT1A receptor partial agonism, along with 5-HT2A receptor antagonism. This receptor activity helps balance dopamine and serotonin levels in the brain. Cariprazine capsules are used to treat schizophrenia, bipolar I disorder (manic or mixed episodes), and as an adjunctive treatment for major depressive disorder (MDD). Its unique D3 activity may offer cognitive and mood-related benefits with a favorable side effect profile.
Product Description:
Cariprazine capsules are FDA-approved in the U.S. for schizophrenia, bipolar I disorder (manic/mixed episodes), and as adjunctive therapy for major depressive disorder (MDD). In the EU, they are approved under the brand name Reagila for schizophrenia via centralized EMA procedures. Regulatory requirements include GMP-compliant manufacturing, robust clinical data, and safety documentation addressing extrapyramidal symptoms (EPS), akathisia, and metabolic effects. U.S. labeling must follow FDA guidance with boxed warnings for elderly dementia-related psychosis. EMA approval mandates detailed pharmacovigilance systems and Risk Management Plans (RMPs). To explore dossier-ready Cariprazine capsules, visit Pharmatradz.com — your global B2B pharma sourcing partner.
Cariprazine Capsules — third party manufacturing & bulk supply
Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Cariprazine Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Cariprazine Capsules →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Cariprazine is used to treat psychiatric conditions such as schizophrenia and bipolar disorder. It helps manage symptoms like hallucinations, delusions, mood swings, and agitation, improving overall mental stability and daily functioning.
Cariprazine is a synthetic pharmaceutical compound that acts as a dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist. It is manufactured under controlled pharmaceutical processes to ensure consistent therapeutic effects and safety.
Cariprazine is marketed under the brand name Vraylar in the United States and other regions.
Cariprazine (Vraylar) is manufactured and marketed by Recordati Pharmaceuticals, with distribution in multiple countries through authorized partners.
The generic name is Cariprazine.
The most recognized brand name is Vraylar.
Cariprazine is manufactured in regulated pharmaceutical facilities that comply with international quality and safety standards, including sites in the United States, Europe, and other approved markets.
Related Products
Lithium Carbonate
Strength:
150 mg, 300 mg, 600 mg
Form: Tablets
Reference Brands: Lithobid (USA/LATAM), Priadel (EU)
View Details
Phenobarbital Sodium
Strength:
65 mg/mL, 130 mg/mL.
Form: Injection
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
